C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523447-35-02

Enrollment

425

Registered

2026-08-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumoccoccal Immunisation

Brief summary

Prespecified local reactions (redness, swelling, and pain at the injection site), Prespecified systemic events (fever, decreased appetite, irritability, and drowsiness/increased sleep), Adverse events (AEs), Serious adverse events (SAEs)

Interventions

DRUGPrevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent

DRUGadsorbed)

DRUGPF-07872412

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Prespecified local reactions (redness, swelling, and pain at the injection site), Prespecified systemic events (fever, decreased appetite, irritability, and drowsiness/increased sleep), Adverse events (AEs), Serious adverse events (SAEs)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 19, 2026